ACORN BIOVENTURES — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BiotechHealthtechGeneva
Roger Mills(Executive Officer, Director)Mikhail Kalinichev(Executive Officer)Jean-Philippe Rocher(Executive Officer)Robert Lutjens(Executive Officer)Timothy Dyer(Executive Officer, Director)Vincent Lawton(Director)
Board seatIsaac Manke· per SEC Form D · $5.9M raise · filed Dec 2021
Co-investorsNew Enterprise Associates (NEA)Sofinnova PartnersSR One Capital Management
Engaged in discovery and development of targeted small molecule therapies for cancer treatment, including selective mutant-specific PI3K inhibitors.
BiotechBoulder, US
Anthony D. Piscopio(Executive Officer, Director)Nicholas Saccomano(Director)Duncan Walker(Executive Officer)James Winkler(Executive Officer)Jason Leverone(Executive Officer)Keith M. Olivia(Executive Officer)
Board seatIsaac Manke· per SEC Form D · $56.6M raise · filed Mar 2022
Co-investorsSamsara BioCapital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.